Hagop Kantarjian, MD[slides]- ALL Treatment:Therapies-Strategies

Exploring Advances and Challenges in ALL Treatment with Hagop Kantarjian, MD: Unveiling Progress with Blinatumomab and Inotuzumab, Introducing the 'Brick Regimen' and Innovations in CAR T-cell Therapy.

MD-Education Photo

MD-Education
3 months 17 Views
Hagop Kantarjian 2
acute lymphoblastic leukemia ALL 5
MD-Education 73
AML-ALL US Focus Meeting 2023 72
Inotuzumab 12
Blinatumomab 15
CART T-cell 10
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
0
0
Category:
Acute Lymphoblastic Leukemia
Description:

Hagop Kantarjian, MD is professor and chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center

Hagop Kantarjian, MD shared exciting updates and progress in the treatment landscape. Notably, some of the predictions made back in 2010 are now proving to be successful. Initiatives like the development of the blinatumomab and inotuzumab therapies started in 2008 and by 2010, it was clear that using them as standalone treatments would not be effective, prompting a shift towards combination therapies.

REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS
AML-ALL US - Online content available - https://aml-allus2023.md-education.com/register/
AML-ALL EU - Registration open - https://aml-alleu2023.md-education.com/register/
MPN-MDS EU - registration open - https://mpn-mdseu2023.md-education.com/register/

However, progress has been gradual. Around 15 years later, challenges persist in finding the optimal treatment regimen for acute lymphoblastic leukemia. One controversial idea proposed is that the emphasis on randomized trials as the sole measure of medical progress might actually be slowing down research advancements. Instead, the speaker suggests moving towards single-arm trials and Bayesian designs in the context of acute leukemias. Despite these challenges, pediatric ALL outcomes have improved significantly, with cure rates reaching 80-90% thanks to intensive chemotherapy.